A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours

U Lassen; L R Molife; Janice Marie Sorensen; S-A Engelholm; L Vidal; R Sinha; R T Penson; P Buhl-Jensen; E Crowley; J Tjornelund; P Knoblauch; J S de Bono

doi:10.1038/sj.bjc.6605726

A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours

U Lassen, L R Molife, Janice Marie Sorensen, S-A Engelholm, L Vidal, R Sinha, R T Penson, P Buhl-Jensen, E Crowley, J Tjornelund, P Knoblauch, J S de Bono

87 Citations (Scopus)

Abstract

This phase I study assessed the maximum tolerated dose, dose-limiting toxicity (DLT) and pharmacokinetics of belinostat with carboplatin and paclitaxel and the anti-tumour activity of the combination in solid tumours.

Original language	English
Journal	British Journal of Cancer
Volume	103
Issue number	1
Pages (from-to)	12-7
Number of pages	6
ISSN	0007-0920
DOIs	https://doi.org/10.1038/sj.bjc.6605726
Publication status	Published - 29 Jun 2010

Access to Document

10.1038/sj.bjc.6605726

Cite this

Lassen, U., Molife, L. R., Sorensen, J. M., Engelholm, S.-A., Vidal, L., Sinha, R., Penson, R. T., Buhl-Jensen, P., Crowley, E., Tjornelund, J., Knoblauch, P., & de Bono, J. S. (2010). A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours. British Journal of Cancer, 103(1), 12-7. https://doi.org/10.1038/sj.bjc.6605726

A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours. / Lassen, U; Molife, L R; Sorensen, Janice Marie et al.
In: British Journal of Cancer, Vol. 103, No. 1, 29.06.2010, p. 12-7.

Research output: Contribution to journal › Journal article › Research › peer-review

Lassen, U, Molife, LR, Sorensen, JM, Engelholm, S-A, Vidal, L, Sinha, R, Penson, RT, Buhl-Jensen, P, Crowley, E, Tjornelund, J, Knoblauch, P & de Bono, JS 2010, 'A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours', British Journal of Cancer, vol. 103, no. 1, pp. 12-7. https://doi.org/10.1038/sj.bjc.6605726

@article{48c021854b3a4d45a32221086e7392bf,

title = "A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours",

abstract = "This phase I study assessed the maximum tolerated dose, dose-limiting toxicity (DLT) and pharmacokinetics of belinostat with carboplatin and paclitaxel and the anti-tumour activity of the combination in solid tumours.",

author = "U Lassen and Molife, \{L R\} and Sorensen, \{Janice Marie\} and S-A Engelholm and L Vidal and R Sinha and Penson, \{R T\} and P Buhl-Jensen and E Crowley and J Tjornelund and P Knoblauch and \{de Bono\}, \{J S\}",

year = "2010",

month = jun,

day = "29",

doi = "10.1038/sj.bjc.6605726",

language = "English",

volume = "103",

pages = "12--7",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours

AU - Lassen, U

AU - Molife, L R

AU - Sorensen, Janice Marie

AU - Engelholm, S-A

AU - Vidal, L

AU - Sinha, R

AU - Penson, R T

AU - Buhl-Jensen, P

AU - Crowley, E

AU - Tjornelund, J

AU - Knoblauch, P

AU - de Bono, J S

PY - 2010/6/29

Y1 - 2010/6/29

N2 - This phase I study assessed the maximum tolerated dose, dose-limiting toxicity (DLT) and pharmacokinetics of belinostat with carboplatin and paclitaxel and the anti-tumour activity of the combination in solid tumours.

AB - This phase I study assessed the maximum tolerated dose, dose-limiting toxicity (DLT) and pharmacokinetics of belinostat with carboplatin and paclitaxel and the anti-tumour activity of the combination in solid tumours.

UR - https://www.scopus.com/pages/publications/77954167626

U2 - 10.1038/sj.bjc.6605726

DO - 10.1038/sj.bjc.6605726

M3 - Journal article

C2 - 20588278

SN - 0007-0920

VL - 103

SP - 12

EP - 17

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 1

ER -

A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours

Abstract

Access to Document

Other files and links

Fingerprint

Cite this